We assessed the impact of TP53 mutation on response rate as defined by CR/CRi, while Welch et al. compared TP53 mutational status and response defined by morphological leukemia free state (MLFS) rate after the first treatment cycle but it was not clear in their description of responders whether patient achieving MLFS after first cycle of decitabine eventually converted to a complete remission or improved OS. Here, TP53 is linked to leukemia.